氨茶碱、乙酰半胱氨酸颗粒联合布地格福治疗稳定期慢性阻塞性肺疾病患者的效果

Effect of Aminophylline and Acetyl Cysteine Granules Combined with Budegophor on Patients with Stable Chronic Obstructive Pulmonary Disease

目的分析稳定期慢性阻塞性肺疾病(COPD)患者应用氨茶碱、乙酰半胱氨酸颗粒联合布地格福治疗的效果。方法收集厦门市同安区祥平社区卫生服务中心2022年3月至2023年12月收治的90例稳定期COPD患者临床资料进行回顾性分析,依照治疗方案差异分为两组,对照组(44例)接受氨茶碱、乙酰半胱氨酸颗粒治疗,观察组(46例)在对照组基础上联合布地格福治疗,比较两组疗效、急性加重住院率、不良反应发生情况、治疗前后呼吸状况[(圣乔治呼吸问卷量表(SGRQ)评分)]、肺功能[(最大自主通气量(MVV)、用力肺活量(FVC)、呼气峰流量(PEF)、一氧化碳弥散量占预计值百分率(DLCO%pred)、最大呼气中期流量(MMEF)、第一秒用力呼气量(FEV_(1))]。结果与对照组比较,观察组总有效率较高(P<0.05);观察组急性加重住院率较对照组低(P<0.05);治疗后,两组SGRQ评分均降低,且观察组更低(P<0.05);治疗后,两组肺功能均有所改善,且观察组FVC、DLCO%pred、FEV_(1)、MVV、PEF、MMEF均较对照组高(P<0.05);两组不良反应发生率无统计学意义(P>0.05)。结论氨茶碱、乙酰半胱氨酸颗粒联合布地格福治疗稳定期COPD患者,能有效提高治疗效果,改善患者呼吸状况、肺功能,降低急性加重住院风险,且不会明显增加用药安全风险。

Objective To analyze the therapeutic effect of aminophylline and acetylcysteine granules combined with budigofo in patients with stable chronic obstructive pulmonary disease(COPD).Methods Clinical data of 90 patients with stable COPD admitted to Xiangping Community Health Service Center,Tongan District,Xiamen City from March 2022 to December 2023 were retrospectively analyzed.According to the differences in treatment plans,they were divided into two groups.The control group(44 cases)received aminophylline and acetylcysteine granules.Observation group(46 cases)was treated with budegforo on the basis of control group.The efficacy,hospitalization rate of acute exacerbations,occurrence of adverse reactions,respiratory status before and after treatment[(St George's Respiratory Questionnaire(SGRQ)score)],lung function[(maximum voluntary ventilation volume(MVV),forced vital capacity(FVC),peak expiratory flow(PEF),carbon monoxide dispersion percentage of predicted value(DLCO%pred),were compared between the two groups,Maximum mid-expiratory flow(MMEF),forced expiratory volume in the first second(FEV_(1))].Results Compared with the control group,the total effective rate of the observation group was higher(P<0.05).The hospitalization rate of acute aggravation in observation group was lower than that in control group(P<0.05).After treatment,SGRQ scores were decreased in both groups,and lower in observation group(P<0.05).After treatment,the lung function of both groups was improved,and FVC,DLCO%pred,FEV_(1),MVV,PEF and MMEF in observation group were higher than those in control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions Aminophylline and acetyl cysteine granules combined with budigerfo in the treatment of stable COPD patients can effectively improve the therapeutic effect,improve the respiratory status and lung function of patients,reduce the risk of acute aggravation hospitalization,and will not significantly increase the safety risk of medication.